Genex Pharmaceutical, Inc (GENX) Fair Value & Analysis
Healthcare · US · Market cap $111K
Genex Pharmaceutical, Inc
GENX · US
Fair value as of: Jun 26, 2026
From 24 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0100 to $0.0001 (−99.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0002 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Genex Pharmaceutical, Inc (GENX) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Genex Pharmaceutical, Inc generated revenue of $3.2M at a net margin of 10.6%. Revenue grew 31.8% year over year. It earns a return on equity of 7.8%. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People's Republic of China. The RBX is a medical device that accelerates bone healing. The company distributes its medical devices to approximately 500 hospitals, as well as to other medical device customers. Genex Pharmaceutical, Inc. was founded in 2003 and is headquartered in Tianjin, the People's Republic of China.
Revenue & earnings trend
FY2003 – FY2007 · reported fiscal years
Genex Pharmaceutical, Inc reported revenue of $3.2M in FY2007 versus $3.5K in FY2003, a compound +452.1%/yr. Reported net income was $343K in FY2007.
Is GENX fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Genex Pharmaceutical, Inc (GENX) undervalued?
What is the fair value of GENX?
What is the quality score of GENX?
What is the revenue of Genex Pharmaceutical, Inc (GENX)?
What is the net profit margin of GENX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.